WA
TARS icon

Waverly Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Waverly Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,197
Closed -$535K – 1319
2025
Q2 		$535K Sell
13,197
-2,812
-18% -$127K 0.01% 780
2025
Q1 		$822K Buy
+16,009
New +$791K 0.01% 649

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Waverly Advisors's TARS Position: Q3 2025 in Review

Waverly Advisors sold out of Tarsus Pharmaceuticals (TARS) in Q3 2025, closing a stake of 13,197 shares — an estimated $535K sold.

Waverly Advisors first reported a position in TARS in Q1 2025 and held it in 2 quarters. The position peaked at $822K in Q1 2025. 220 funds tracked by Wall St. Rank hold TARS as of Q3 2025.

  • Waverly Advisors reported no remaining Tarsus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Waverly Advisors sold 13,197 Tarsus Pharmaceuticals shares in Q3 2025, an estimated $535K.
  • Waverly Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Waverly Advisors's Tarsus Pharmaceuticals position peaked at $822K in Q1 2025.
  • 220 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2025.

Based on Waverly Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.